chr5-177402460-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 9P and 1B. PVS1PP5BS1_Supporting
The NM_000505.4(F12):c.1681-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00034 in 1,604,662 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000505.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000322 AC: 49AN: 152258Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000405 AC: 93AN: 229800Hom.: 0 AF XY: 0.000352 AC XY: 44AN XY: 124910
GnomAD4 exome AF: 0.000342 AC: 497AN: 1452404Hom.: 0 Cov.: 31 AF XY: 0.000350 AC XY: 253AN XY: 721974
GnomAD4 genome AF: 0.000322 AC: 49AN: 152258Hom.: 0 Cov.: 33 AF XY: 0.000255 AC XY: 19AN XY: 74390
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2023 | F12: PVS1 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 15, 2024 | This sequence change affects an acceptor splice site in intron 13 of the F12 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is present in population databases (rs199988476, gnomAD 0.5%). Disruption of this splice site has been observed in individual(s) with F12-related conditions (PMID: 8528215, 9354665, 25524745, 33727708). ClinVar contains an entry for this variant (Variation ID: 1166). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 21, 2024 | Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Published functional studies demonstrate the variant causes removal of the last exon, resulting in a truncated transcript and unstable protein (PMID: 8528215); Observed in the heterozygous state in an individual with recurrent angioedema and in the compound heterozygous state in individuals with Factor XII deficiency (PMID: 25524745, 9354665); This variant is associated with the following publications: (PMID: 33727708, 21920016, 24029428, 9354665, 23348723, 34426522, 25524745, 31980526, 35866546, 36685169, 8528215) - |
Factor XII deficiency disease Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 18, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 1995 | - - |
F12-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | The c.1681-1G>A variant has been reported in at least three studies and is found in a total of one patient in a homozygous state, four patients in a compound heterozygous state and four patients in a heterozygous state (Schloesser et al. 1995; Schloesser et al. 1997; Xu-Cai et al. 2011). The c.1681-1G>A variant was also observed in a heterozygous state in four offspring of one of the compound heterozygote patients. These individuals also exhibited reduced factor XII activity and antigen levels. Gelincik et al. (2015) identified the c.1681-1G>A variant in a heterozygous state in one patient with HAE with normal C1-INH (type 3 HAE). Factor XII levels were within normal limits in this patient. The c.1681-1G>A variant was absent from 74 control individuals and is reported at a frequency of 0.00077 in the European (non-Finnish) population of the Exome Aggregation Consortium. Transcript analysis in two compound heterozygous patients and one homozygous patient with factor XII deficiency demonstrated aberrant splicing, suggesting that the c.1681-1G>A splice acceptor variant results in detectable transcript but unstable protein (Schloesser et al. 1995). Based on the collective evidence, the c.1681-1G>A variant is classified as likely pathogenic for F12-related disorders. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at